Neumora Therapeutics, Inc. (NMRA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Neumora Therapeutics reported revenue of $0. Net income was -$236.9M, or -$1.45 per diluted share. Operating activities generated -$206.4M of cash. At fiscal year end, Neumora Therapeutics held $191.0M in total assets against $87.2M in total liabilities, including $182.5M of cash and equivalents.
Open the full interactive Neumora Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Neumora Therapeutics Key Stats
| Share Price | $0.37 |
|---|---|
| Market Cap | $68.5M |
| 52-Week Range | $0.37 – $3.59 |
| Shares Outstanding | 185.2 million (basic, 2026 Q2) |
Neumora Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$252.1M | -$263.5M | -$241.2M |
| Pre-Tax Income | -$235.7M | -$243.6M | -$236.8M |
| Income Tax | $268,000 | $178,000 | $130,000 |
| Net Income | -$235.9M | -$243.8M | -$236.9M |
| Diluted EPS | -$3.63 | -$1.53 | -$1.45 |
Neumora Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$56.8M | -$59.5M | -$53.5M | -$43.1M |
| Diluted EPS | -$0.35 | -$0.36 | -$0.30 | -$0.23 |
Neumora Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $374.0M | $142.1M | $182.5M |
| Current Assets | $478.3M | $314.1M | $190.5M |
| Total Assets | $496.2M | $317.0M | $191.0M |
| Current Liabilities | $25.1M | $29.9M | $32.5M |
| Total Long-Term Debt | — | — | $114.5M |
| Total Liabilities | $27.1M | $29.9M | $87.2M |
| Shareholders' Equity | $469.1M | $287.1M | $103.9M |
Neumora Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$163.3M | -$182.9M | -$206.4M |
| Cash From Investing | $64.4M | -$70.6M | $168.5M |
| Cash From Financing | $231.9M | $21.6M | $77.1M |
| Free Cash Flow | -$163.4M | -$183.1M | — |
Figures from Neumora Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neumora Therapeutics financials page for every line item.
Neumora Therapeutics Company Profile
| Ticker | NMRA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001885522 |
Frequently Asked Questions
What was Neumora Therapeutics' revenue in fiscal 2025?
Neumora Therapeutics (NMRA) reported revenue of $0 for fiscal 2025.
What is Neumora Therapeutics' annual revenue history?
Neumora Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Neumora Therapeutics' net income in fiscal 2025?
Neumora Therapeutics reported net income of -$236.9M for fiscal 2025.
What was Neumora Therapeutics' earnings per share (EPS) in fiscal 2025?
Neumora Therapeutics' diluted EPS was -$1.45 for fiscal 2025 (adjusted for any later stock splits).
What was Neumora Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Neumora Therapeutics reported revenue of $0.
How much debt does Neumora Therapeutics have?
Neumora Therapeutics reported $114.5M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Neumora Therapeutics are outstanding?
Neumora Therapeutics reported a weighted average of 185.2 million basic shares outstanding in 2026 Q2.
What is Neumora Therapeutics' market cap?
Based on its latest closing price, Neumora Therapeutics (NMRA) has a market capitalization of about $68.5M.
When does Neumora Therapeutics' fiscal year end?
Neumora Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Neumora Therapeutics headquartered?
Neumora Therapeutics lists its business address in Watertown, Massachusetts in its SEC filings.
Neumora Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →